Results 111 to 120 of about 9,029,710 (297)

Guillain-Barré syndrome: a century of progress [PDF]

open access: yes, 2016
In 1916, Guillain, Barré and Strohl reported on two cases of acute flaccid paralysis with high cerebrospinal fluid protein levels and normal cell counts — novel findings that identified the disease we now know as Guillain–Barré syndrome (GBS).
A Campbell   +91 more
core   +1 more source

Bibliometric analysis of the intestinal microbiota and demyelinating diseases, particularly multiple sclerosis, since 2014

open access: yesFrontiers in Neuroscience
BackgroundThe gut–brain axis (GBA) represents a complex, bidirectional communication network that connects the central nervous system (CNS) and the gastrointestinal system.
Ling Chen   +4 more
doaj   +1 more source

Diffusion Kurtosis Imaging maps neural damage in the EAE model of multiple sclerosis [PDF]

open access: yesarXiv, 2018
Diffusion kurtosis imaging (DKI), is an imaging modality that yields novel disease biomarkers and in combination with nervous tissue modeling, provides access to microstructural parameters. Recently, DKI and subsequent estimation of microstructural model parameters has been used for assessment of tissue changes in neurodegenerative diseases and their ...
arxiv  

Severe relapse after cessation of immunosuppressive therapy in a patient with co‐occurrence of neuromyelitis optica spectrum disorder and Sjögren's syndrome: A case report

open access: yesIbrain, EarlyView.
We report a girl with a diagnosis of “neuromyelitis optica spectrum disorder comorbid Sjogren's syndrome” whose condition showed significant improvement after treatment with corticosteroids and immunosuppressive drugs (prednisolone, hydroxychloroquine, and mycophenolate mofetil).
Man‐Min Zhu   +3 more
wiley   +1 more source

Bypassing damaged nervous tissue [PDF]

open access: yesarXiv, 2016
It is shown the principal possibility of bypassing damaged demyelinated portions of the nervous tissue, thereby restoring its normal function for the passage of action potentials.
arxiv   +1 more source

Increased age and male sex are independently associated with higher frequency of blood–cerebrospinal fluid barrier dysfunction using the albumin quotient [PDF]

open access: yes, 2020
Background: The cerebrospinal fluid (CSF)/serum quotient of albumin (QAlb) is the most used biomarker for the evaluation of blood–cerebrospinal fluid barrier (B-CSF-B) permeability.
Alessi, Francesca   +12 more
core   +1 more source

Neuroprotective therapies for multiple sclerosis and other demyelinating diseases

open access: yesMultiple Sclerosis and Demyelinating Disorders, 2016
Damage to the Central Nervous Systems (CNS) in Multiple Sclerosis (MS) seems to be mainly due to chronic inflammation of the CNS with superimposed bouts of inflammatory activity by the adaptive immune system.
P. Villoslada
semanticscholar   +1 more source

Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE Study

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced in 2018 as a device‐aided therapy for advanced Parkinson's disease (PD). Objectives The ELEGANCE study (NCT05043103) is gathering real‐world data on long‐term efficacy, safety and patient‐reported outcomes with LECIG from 13 European countries.
Daniel Weiss   +10 more
wiley   +1 more source

Multivariate MR Biomarkers Better Predict Cognitive Dysfunction in Mouse Models of Alzheimers Disease [PDF]

open access: yesarXiv, 2018
To understand multifactorial conditions such as Alzheimers disease (AD) we need brain signatures that predict the impact of multiple pathologies and their interactions. To help uncover the relationships between brain circuits and cognitive markers we have used mouse models that represent, at least in part, the complex interactions altered in AD.
arxiv  

Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. [PDF]

open access: yes, 2018
Anti-MAG demyelinating neuropathy is difficult to treat. All immunotherapies have failed except for rituximab, a chimeric B-cell–depleting monoclonal antibody against CD20, that helps up to 40% of patients based on 2 controlled and several uncontrolled ...
Dalakas, Marinos C.   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy